Enhanced proliferation over the existing “stiff” beads that are currently used in clinical trials
Adoptive T cell therapy has emerged as a powerful way of treating a number of metastatic cancers. The effectiveness of this therapy depends on obtaining a sufficient number of T cells during the in vitro proliferation step, together with the ideal phenotype for the treatment. We have developed a biocompatible, flexible hydrogel bead functionalised with T cell stimulating antibodies which resulted in enhanced proliferation over the existing “stiff” beads that are currently used in clinical trials. The patented technology is available to licence. Please press “Connect” and we will send you 6 supporting Powerpoint slides on this technology. Whenc ontacting us, please quote reference number 6384.